Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email in the first instance.

 Information  X 
Enter a valid email address

Hikma Pharm PLC Ord Shs 10P (HIK)

Related News

11-May-2016 08:00 AM

Broker Forecast - Barclays Capital issues a broker note on Hikma Pharmaceuticals PLC

Barclays Capital today reaffirms its overweight investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 2800p (from 2760p). Story provided by
18-Feb-2016 08:00 AM

Broker Forecast - Jefferies International issues a broker note on Hikma Pharmaceuticals PLC

Jefferies International today reaffirms its buy investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and cut its price target to 2355p (from 2555p). Story provided by
11-Feb-2016 12:26 PM

Hikma publishes supplementary combined prospectus and circular

Hikma Pharmaceuticals has today published a supplementary combined prospectus and circular, which is a supplement to the combined prospectus and circular published by the Company on 22 January 2016 in relation to the Acquisition and Consideration Shares.
14-Jan-2016 08:00 AM

Broker Forecast - Jefferies International issues a broker note on Hikma Pharmaceuticals PLC

Jefferies International today reaffirms its buy investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and cut its price target to 2555p (from 2615p). Story provided by
02-Nov-2015 08:49 AM

Hikma's Generics arm below expectations

Hikma Pharmaceuticals says it is performing well across most of its businesses, particularly Injectables and in its MENA markets. But it says trading in its Generics business is currently below expectations due to slower than expected growth in colchi
08-Sep-2015 08:05 AM

Hikma to acquire EIMC United Pharmaceuticals

Hikma Pharmaceuticals has agreed to acquire 98.09% of the share capital of EIMC United Pharmaceuticals from a consortium of shareholders. EUP is a pharmaceutical manufacturing company specialising in oncology products. Hikma says the acquisition of
19-Aug-2015 07:34 AM

Hikma guides

Hikma reports a solid H1 performance in line with expectations and is on track to achieve full year guidance. It said revenues of $709m were in line with H1 2014 in constant currency, but down 4% on a reported basis, with good performances from Branded an
14-May-2015 08:12 AM

Hikma reiterates guidance

Hikma Pharmaceuticals has reiterated its full year guidance for the group and each of its business segments after making a good start to the year. Shareholders at today annual general meeting will be told that the group expects full year revenue growth o
12-May-2015 09:07 AM

Hikma launches caffeine citrate injection

Hikma Pharmaceuticals has launched CAFCIT Injection (caffeine citrate injection, USP) 60mg/3mL (20mg/mL). CAFCIT is indicated for the short-term treatment of apnea of prematurity in infants between 28 and 33 weeks gestational age. Chairman and chief e
11-Mar-2015 08:41 AM

Hikma profits up

Hikma Pharmaceuticals reports an excellent performance in 2014 with strong underlying growth. Group revenue for the year to the end of December increased by 9% to $1,489m, driven by strong growth in Injectables. Profit attributable to shareholders incr
27-Jan-2015 02:35 PM

Hikma gives insights on MENA growth markets

Hikma Pharmaceuticals joined the 45th World Economic Forum (WEF) Annual Meeting in Davos-Klosters, Switzerland, held on 21-24 January, to provide insights on the impact of recent societal, political and economic developments on growth markets in the Arab
12-Jan-2015 07:42 AM

Hikma to launch colchicine 0.6mg capsules

Hikma Pharmaceuticals notes that Takeda Pharmaceuticals USA. Inc has been unsuccessful in appealing the decision by the United States District Court for the District of Delaware to deny Takeda's motion for a preliminary injunction in relation to the
06-Nov-2014 09:07 AM

Hikma Pharmaceuticals raises revenue guidance

Hikma Pharmaceuticals reports a strong performance in its Injectables, Branded and Generics businesses and has raised its guidance for 2014 group revenue growth of around 7%. The group says its financing position remains very strong and will enable it
24-Oct-2014 07:16 AM

Hikma's letter

Hikma Pharmaceuticals has received a 'warning letter' from the US Food and Drug Administration related to the inspection of its manufacturing facility in Portugal in March. In the letter, the agency raised issues related to investigations and
01-Oct-2014 07:26 AM

Hikma gets FDA approval for colchicine capsules

Hikma Pharmaceuticals has received approval of its new drug application for colchicine 0.6mg capsules by the US Food and Drug Administration. Hikma will market its colchicine under the brand name MITIGARE. MITIGARE is indicated for prophylaxis of gout
17-Sep-2014 07:34 AM

Hikma completes acquisition of Ben Venue site

Hikma Pharmaceuticals has completed its acquisition of substantially all of the assets of the generic injectables manufacturing site of Ben Venue Laboratories, part of the Boehringer Ingelheim Group of Companies, as agreed on 24 July . The Ben Venue sit
20-Aug-2014 08:23 AM

Hikma revenues up 16%

Hikma Pharmaceuticals reports an excellent first half with 16% revenue growth and a 44% increase in adjusted earnings per share. Hikma said group revenue increased by 16% to $738m, driven by the very strong performance of its Injectables business in t
24-Jul-2014 09:14 AM

Hikma to acquire Ben Venue manufacturing site

Hikma Pharmaceuticals agreed with Ben Venue Laboratories - part of the Boehringer Ingelheim Group - to acquire substantially all of its generic injectables manufacturing site in Bedford, Ohio. The acquisition is pursuant to the exclusivity arrangement
15-Jul-2014 04:02 PM

Hikma completes acquisition of assets of Bedford Laboratories

Hikma Pharmaceuticals has completed its acquisition of assets of the US generic injectables business, Bedford Laboratories from Ben Venue Laboratories, a member of the Boehringer Ingelheim Group of Companies. As previously announced, the total consider
28-May-2014 12:12 PM

Hikma Pharmaceuticals makes $300m US investment

Hikma Pharmaceuticals (LSE: HIK), the multinational pharmaceutical group, has signed an asset purchase agreement with Ben Venue Laboratories, a member of the Boehringer Ingelheim Group of Companies, to acquire assets of Bedford Laboratories, its US generi
15-May-2014 08:25 AM

Hikma reiterates FY guidance

Hikma Pharmaceuticals has made a strong start to the year and is reiterating its guidance for 2014 of around 5% group revenue growth, following an exceptionally strong year in 2013. Chief executive Said Darwazah said: "Our efforts to build a broad
02-Apr-2014 08:27 AM

FDA lifts 'warning letter' on Hikma facility

Hikma Pharmaceuticals says it has resolved issues raised by the US Food and Drug Administration in February 2012. Hikma says it has received a close-out letter from the FDA that lifts the warning letter about the Eatontown facility in New Jersey, which
12-Mar-2014 08:24 AM

Hikma unveils board and management changes

Hikma Pharmaceuticals has announced changes to its board composition and organisational structure. Mazen Darwazah is to be promoted to the new position of president and chief executive of MENA and emerging markets. Darwazah's additional responsibi
12-Mar-2014 07:26 AM

Hikma to pay special dividend as full-year earnings surge

Hikma Pharmaceuticals said it delivered an excellent performance in 2013 with revenue growth of 23% and EPS up 111%. Profit attributable to shareholders increased by 112% to $212m in the year to end-December. Hikma said it expects continued growth in 20
11-Feb-2014 02:37 PM

Hikma chairman to step down

Hikma Pharmaceuticals has unveiled a raft of board changes which will take effect from the annual general meeting on 15 May. Non-executive chairman Samih Darwazah will retire from the board and become honorary life president while chief executive Said
Top categories
Company finder